Navigation Links
Roche to Acquire Ventana for $89.50 per share
Date:1/22/2008

dge work in advancing disease detection and treatment. Our diagnostics and pharmaceuticals businesses in the U.S. employ more than 20,000 people and generate approximately $10 billion in sales (including Genentech), accounting for about 40% of the Roche Group's global annual revenues.
For further information, please visit http://www.roche.com.

All trademarks used or mentioned in this release are protected by law.

About Ventana Medical Systems

Ventana develops, manufactures, and markets instrument/reagent systems that automate tissue preparation and slide staining in clinical histology and drug discovery laboratories worldwide. The company's clinical systems are important tools used in the diagnosis and treatment of cancer and infectious diseases. Ventana's drug discovery systems are used to accelerate the discovery of new drug targets and evaluate the safety of new drug compounds. Visit the Ventana Medical Systems, Inc. website at http://www.ventanamed.com.

Further information

- All documents on the offer to Ventana's shareholders: http://www.roche.com/info070625

Contacts for Roche:

Roche Group Media Office

Phone: +41 61 688 8888 / e-mail: basel.mediaoffice@roche.com

- Daniel Piller (Head of Roche Group Media Office)

- Alexander Klauser

Brunswick Group (for U.S. media)

Phone: +1 212 333 3810

- Steve Lipin

- Nina Devlin

MacKenzie Partners (for U.S. investors)

Phone: +1 212 929 5500

-Larry Dennedy

-Bob Marese

Contacts for Ventana:

Sard Verbinnen & Co (for media)

Phone: +1 212 687 8080

Anna Cordasco

Brooke Morganstein

Innisfree M&A Incorporated (for investors)

Phone: +1 212 750 5833

<
'/>"/>
SOURCE Roche; Ventana Medical Systems
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Roche Extends Tender Offer for Ventana
2. Amic Signs Non-Exclusive License Agreement With Roche Diagnostics for Key Cardiac Marker NT-proBNP
3. Roche Files IND for Second Genmab Antibody
4. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
5. Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting
6. MacroChem to Present at Equities Magazine Conference December 7, 2007 in New York
7. Roche Diagnostics Launches CoaguChek XS Plus System to Provide New PT/INR Point-of-Care Solution for Non-Waived Anticoagulation Services
8. Kosan to Reacquire Epothilone Program From Roche
9. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
10. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
11. MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... (PRWEB) July 31, 2014 The global ... 8,020.1 million by 2020, according to a new study ... medicine and theranostics, and the subsequent introduction of advanced ... driving market growth over the next six years. Moreover, ... diseases such as cancer, coupled with disease triggering lifestyle ...
(Date:7/31/2014)... Wash. , July 31, 2014   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... media and precision thermal shipping products for ... second quarter 2014 financial results will be released on ... host a conference call and live webcast at 4:30 ...
(Date:7/31/2014)... MA (PRWEB) July 31, 2014 Boston’s ... finds itself flush with innovative adult stem cell biotechnologies. ... patents and has three additional patent applications currently ... , The patented inventions address two of the most ... regenerative medicine. Adult stem cells are difficult to ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today ... Food and Drug Administration (FDA) rare pediatric disease priority ... (BLA) submission for alirocumab.  The priority review voucher entitles ... which provides for an expedited 6-month review from the ...
Breaking Biology Technology:Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6
... of Iowa and the University of Missouri (MU) have developed ... closely mimic the disease in human infants. The striking similarities ... with CF suggest that this new model will help improve ... new treatments. The study is published in the Sept. 26 ...
... Complement Inhibition and,Impact of Soliris on Patients Living ... Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ) has received ... Product for Soliris(R) (eculizumab). The Award,recognizes the scientific ... the impact the drug is,having on the lives ...
... Industry Leaders to Spearhead and Expand Home ... Health Care Services Business, CHICAGO, ... focused exclusively on the health care,industry, announced today that it has ... to acquire a controlling interest in,CareCentrix. The firm also announced that ...
Cached Biology Technology:Researchers develop new model for cystic fibrosis 2Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 2Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 3Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 4Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 5Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix 2Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix 3Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix 4
(Date:7/31/2014)... By tracing nearly 3,000 genes to the earliest ... Florida scientists have created an extensive "Tree of ... next-generation DNA sequencing. , Among the study,s ... to small moths than to large ones, which ... The study also found that some insects once ...
(Date:7/31/2014)... (HPV-023; NCT00518336) shows the sustained efficacy, immunogenicity ... (HPV) vaccine Cervarix. Women vaccinated with the ... than nine years, and vaccine efficacy (VE) ... the longest follow-up report for a licensed ... the full paper. , HPV and ...
(Date:7/31/2014)... German . ... to a sponge that soaks up liquids. Hence, these ... greenhouse gases. However, loading of many MOFs is inhibited ... now report in Nature Communications that the ... This can be prevented by water-free synthesis and storing ...
Breaking Biology News(10 mins):UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3Free pores for molecule transport 2
... its fluid membranes to carry out critical ... or sorting proteins.,Because membranes are fluid and ... in detail has always been,difficult. But a ... of physics at Carnegie Mellon University, provides ...
... Carbon nanotubes are 10,000 times thinner than a human ... diamonds. They conduct heat and electricity with efficiency that ... in everything from concrete and clothes to bicycle parts ... wonder material for what could become a multi-billion dollar ...
... crops have been widely adopted by American farmers. In ... European Union (EU) imposed a 6-year freeze (19982004) on ... aid to African nations was rejected by the recipient ... contributed to this decision. , Lori Unruh Snyder, Department ...
Cached Biology News:Carnegie Mellon develops computer model to study cell membrane dynamics 2Carnegie Mellon develops computer model to study cell membrane dynamics 3Making sure the wonder materials don't become the wonder pollutant 2
... Microarrays designed for pathway studies, ... protein (PTB) Studies built on the ... synthesis platform. These microarrays are available ... Peptide Microarray Service. Custom ...
... normal Mega Western Protein Array was developed ... Western Protein Arrays are manufactured using high ... sources. A protein sample from each of ... a Protein molecular weight marker on a ...
... Superior Protein Detection and Quantitation Over ... Proteomic Imaging System is a highly sensitive ... life science research applications. ProXPRESS 2D provides ... dyes in the UV and VIS spectrum ...
... 7 lanes of total ... brain tissue including: precentral ... lobe, temporal lobe, parietal ... cerebellum. Patent/trademark/license (electronic): Manufactured ...
Biology Products: